Answer
The most common adverse reaction with guselkumab (Tremfya) was respiratory tract infections, affecting approximately 8% of ulcerative colitis patients, 11% of Crohn's disease study patients, and 15% of psoriasis and psoriatic arthritis clinical study patients.
Sources for this answer
- Tremfya 100 mg OnePress solution for injection in pre-filled penJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 16Document updated
Sources checked